Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region
Overview
Authors
Affiliations
Background: Racial disparities in non-Hodgkin lymphoma (NHL) are not well-elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities.
Materials And Methods: Using Surveillance, Epidemiology, and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL incidence rates by lymphoma subtype and racial differences in baseline characteristics and outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Cox regression models identified predictors of overall survival (OS).
Results: SEER documented 38,504 NHL cases in Georgia from 2001 to 2015. The age-adjusted incidence rate for NHL in Georgia increased 1.03% per year, and the annual percentage change was 1.72 in blacks compared with 0.84 in whites. Compared with whites, blacks with DLBCL and FL were more likely to be diagnosed at a younger age (DLBCL, 54.1 vs. 65.5 years; P < .0001; FL, 58.4 vs. 64.0 years; P < .0001) and with B symptoms (DLBCL, 44.4% vs. 33.4%; P < .0001; FL, 28.5% vs. 21.4%; P = .004). Across racial categories, age at diagnosis > 60 years, advanced stage, and B symptoms predicted worse OS in DLBCL and FL. Blacks with DLBCL more commonly were diagnosed with stage III/IV disease (55.5% vs. 48.1%; P < .0001) and had worse 5-year relative survival (58.8% vs. 62.3%; P = .01).
Conclusions: Regional cancer registry data can be used to define incidence patterns and disparities in outcomes across NHL subtypes to help define key targets for interventions in a catchment area.
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.
de Campos C, McCabe C, Bruins L, OBrien D, Brown S, Tschumper R Blood Cancer J. 2025; 15(1):14.
PMID: 39910036 PMC: 11799526. DOI: 10.1038/s41408-024-01207-3.
New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials.
Nze C, Herrera A Blood Adv. 2024; 9(4):774-782.
PMID: 39631075 PMC: 11869956. DOI: 10.1182/bloodadvances.2024012981.
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D Blood. 2024; 143(26):2722-2734.
PMID: 38635762 PMC: 11251200. DOI: 10.1182/blood.2023023447.
Hepatitis B Virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities.
Rosenberg M, Poluch M, Thomas C, Sindaco P, Khoo A, Porcu P Front Oncol. 2023; 13:1275800.
PMID: 37927464 PMC: 10623156. DOI: 10.3389/fonc.2023.1275800.
Parsons M, Rock C, Chipman J, Shah H, Hu B, Stephens D Cancer Med. 2023; 12(3):2624-2636.
PMID: 36812123 PMC: 9939160. DOI: 10.1002/cam4.5139.